Arjo receives the Allbright Prize 2024
The medical technology company Arjo has been awarded the 2024 Allbright Prize for purposeful and long-term work with equality, diversity and inclusion. The prize was awarded at a ceremony in Stockholm today.
Allbright, a non-partisan and non-profit foundation that works for equality and diversity in management teams, writes in its motivation: "Arjo is a shining example of how conscious and systematic work for equality and diversity can create a more inclusive workplace and at the same time contribute to business success."
"With a genuine commitment, Arjo has also identified structures
”Growth continued in the quarter with a strengthened order book and improved gross margin. Our performance was, however, held back by weaker demand in Europe. We are now accelerating initiatives to improve both short- and long-term profitability. We enter the final quarter of the year with high activity level and expect to reach our ambition of 3-5% organic growth for the full-year,” says Joacim Lindoff, President and CEO of Arjo.
July-September 2024 in brief
· Net sales amounted to SEK 2,734 M (2,777).
Net sales grew organically by 1.5%.
· The gross margin increased to 42.0%
”The recovery following a turbulent 2022 continues and we grew 5% organically with improved profitability and strong cash flow. Demand was healthy in many markets and despite continuing challenging market conditions in the US, we expect to deliver organic growth for the full-year within our target interval of 3–5%,” says Joacim Lindoff, President and CEO of Arjo.
April-June 2023 in brief
· Net sales increased to SEK 2,686 M (2,404).Net sales grew organically by 5.0%. · Adjusted EBITDA rose to SEK 490 M (430). · Adjusted operating profit increased to SEK 206 M (165). ·
”The Group grew organically by 4.3%, giving us a stable start to the year. Demand for Arjo’s products and solutions was high, and despite a volatile market we remain confident that we will reach the target of 3–5% organic growth for the full-year,” says Joacim Lindoff, President and CEO of Arjo.
January-March 2023 in brief
· Net sales increased to SEK 2,638 M (2,370).Net sales grew organically by 4.3%. · Adjusted EBITDA amounted to SEK 474 M (490). · Adjusted operating profit amounted to SEK 196 M (237). · Profit after financial items amounted to SEK 126 M (218). ·
”We close a year in which growth was primarily held back by lower critical care rental volumes in the US compared with 2021. Adjusted for this the Group grew organically by approximately 3% in 2022, which demonstrates the strength of our underlying business. During the fourth quarter, growth continued across all major markets outside the US, and we report an adjusted EBITDA-result of SEK 500 M. In addition, reduced inventory levels contribute to a cash conversion above our target,” says Joacim Lindoff, President and CEO of Arjo.
“We manage the short-term challenges in our environment and